Concord Biotech IPO
Concord Biotech IPO — date, price band, lot size & details 2023
Concord Biotech listed on 18 Aug 2023 at ₹900.05, 21.5% above the ₹741 issue price.
Concord Biotech is a biopharma company and one of the leading global makers of select fermentation-based APIs in immunosuppressants and oncology. Its total income was Rs 888.48 crore in FY2023.
Stock price
Concord Biotech is listed — here is the live share price.
Timetable
Key dates from opening to listing. Today is 17 November.
- Open 04 Aug 2023
- Close 08 Aug 2023
- Allotment 11 Aug 2023
- Refund/credit 14 Aug 2023
- Listing 18 Aug 2023
Issue summary
The terms of the offer, as filed.
| IPO Dates | 4 to 8 Aug, 2023 |
|---|---|
| Price Band | ₹705 – ₹741 |
| Face Value | ₹1 |
| Lot Size | 20 Shares |
| Issue Size | ₹1550.52 Cr |
| Sale Type | OFS only |
| Listing On | BSE, NSE |
| Employee Discount | Rs 70.00 per share |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,820 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 20 shares at the ₹741 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 20 | ₹14,820 |
| Retail (max) | 13 | 260 | ₹1,92,660 |
| S-HNI (min) | 14 | 280 | ₹2,07,480 |
| S-HNI (max) | 67 | 1,340 | ₹9,92,940 |
| B-HNI (min) | 68 | 1,360 | ₹10,07,760 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Total income rose from Rs 630.75 crore in FY2021 to Rs 888.48 crore in FY2023.
- 02Profit after tax rose from Rs 174.93 crore in FY2022 to Rs 240.08 crore in FY2023.
- 03The source puts the PAT margin at 28.14%.
- 04Borrowing was low at Rs 31.24 crore on 31 March 2023, against net worth of Rs 1,290.00 crore.
- 05It had over 200 customers in over 70 countries.
Risks · 5
- 01The whole Rs 1,550.52 crore issue was offer for sale, so no money went to the company.
- 02The P/E was 32.29 at the upper band of Rs 741, based on EPS of Rs 22.95.
- 03Profit fell from Rs 234.89 crore in FY2021 to Rs 174.93 crore in FY2022, so results can swing.
- 04API exports face strict regulatory inspections in markets such as the USA, and a few products drive much of the sales from its 23 APIs.
- 05Promoters and the promoter group held only 44.08% before and after the issue.
Three years of numbers
All figures in ₹ crore, as reported in the Concord Biotech offer document.
| Metric | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|
| Assets | 1,513.98 | 1,312.80 | 1,182.55 |
| Total Income | 888.48 | 736.35 | 630.75 |
| Profit After Tax | 240.08 | 174.93 | 234.89 |
| NET Worth | 1,290.00 | 1,103.22 | 999.37 |
| Total Borrowing | 31.24 | 60.59 | 86.35 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Concord Biotech RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Concord Biotech IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹22.95 | ₹22.95 |
| P/E Ratio (x) | 32.29 | 32.29 |
| Market Cap at Offer Price (₹ Cr) | ₹7,751.60 | ₹7,751.60 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹741 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
How the company intends to use the proceeds of the issue.
Information about the usage of proceeds from the Concord Biotech IPO will be updated shortly.
Concord Biotech IPO Anchor Investors
41 anchor investors across 25 fund houses committed ₹464.96 Cr a day before the issue opened.
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
It makes APIs through fermentation and semi-synthetic processes, and also makes finished formulations. Its therapy areas include immunosuppressants, anti-bacterials, oncology and antifungals.
On 31 March 2023 it had 23 APIs and 77 approved products for formulations, and over 200 customers in over 70 countries, including the USA, Europe and Japan.
The IPO was Rs 1,550.52 crore and was entirely an offer for sale by Helix Investment Holdings, which sold its whole 20% stake. The company and the promoters received none of the money.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Concord Biotech IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Kotak Mahindra Capital Company Limited
204 issues handledBest listing: Premier Energies (+120.0%). Weakest: Puravankara Projects (-22.5%).
Jefferies India Private Limited
41 issues handledBest listing: Nazara Technologies (+80.7%). Weakest: Turtlemint Fintech Solutions (-10.4%).
Citigroup Global Markets India Pvt. Ltd
74 issues handledBest listing: Tata Technologies (+140.0%). Weakest: Puravankara Projects (-22.5%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Concord Biotech?
The current Grey Market Premium is ₹67.67, or 9% over the issue price.
What is the Concord Biotech IPO price band?
₹705 to ₹741, on a face value of ₹1.
When is the allotment?
The basis of allotment is 11 August 2023, with listing on 18 August 2023.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.